Literature DB >> 14563341

Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention.

Ping-Yen Liu1, Yi-Heng Li, Wei-Chuan Tsai, Ting-Hsing Chao, Liang-Miin Tsai, Hua-Lin Wu, Jyh-Hong Chen.   

Abstract

AIM: To evaluate the serial changes of plasma secretory type II phospholipase A(2)(sPLA(2)), C-reactive protein (CRP) and cardiac injury markers in coronary artery disease (CAD) patients undergoing percutaneous coronary intervention (PCI) and their prognostic impacts. METHODS AND
RESULTS: Plasma levels of sPLA(2), CRP, creatine kinase (CK), CK-MB and troponin-T were measured in 247 consecutive CAD patients receiving PCI procedure and 100 control subjects without CAD. In CAD group, serial blood samples were taken before coronary angiography, after coronary angiography, immediately after PCI, 24-h and 48-h after PCI. The sPLA(2)and CRP levels did not change after coronary angiography. The level of sPLA(2)significantly increased immediately after PCI. Creatine kinase and cardiac injury markers did not rise immediately after PCI, but elevated significantly at 24h after intervention. After a 2-year follow up, increased sPLA(2)(>450 ng/dl) after PCI, smoking and diabetes mellitus were the independent risk factors for subsequent coronary events (odds ratios 2.1, 2.3 and 3.1, respectively) in patients with CAD.
CONCLUSION: The present study showed that PCI might cause immediate elevation of circulating levels of sPLA(2)following the mechanical disruption of coronary plaque, and the elevated level of sPLA(2)had significant prognostic impact.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14563341     DOI: 10.1016/j.ehj.2003.07.003

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  14 in total

1.  The catalytically active secretory phospholipase A2 type IIA is involved in restenosis development after PTCA in human coronary arteries and generation of atherogenic LDL.

Authors:  Aleksandra A Korotaeva; Elena V Samoilova; Aleksander I Kaminny; Aleksandra A Pirkova; Therese J Resink; Paul Erne; Nina V Prokazova; Vsevolod A Tkachuk; Evgeny I Chazov
Journal:  Mol Cell Biochem       Date:  2005-02       Impact factor: 3.396

2.  Group IIA Secretory Phospholipase A2, Vascular Inflammation, and Incident Cardiovascular Disease.

Authors:  Akintunde O Akinkuolie; Patrick R Lawler; Audrey Y Chu; Michael Caulfield; Jianying Mu; Bo Ding; Fredrik Nyberg; Robert J Glynn; Paul M Ridker; Eva Hurt-Camejo; Daniel I Chasman; Samia Mora
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-06       Impact factor: 8.311

3.  Prognostic utility of secretory phospholipase A(2) in patients with stable coronary artery disease.

Authors:  Michelle L O'Donoghue; Ziad Mallat; David A Morrow; Joelle Benessiano; Sarah Sloan; Torbjørn Omland; Scott D Solomon; Eugene Braunwald; Alain Tedgui; Marc S Sabatine
Journal:  Clin Chem       Date:  2011-07-22       Impact factor: 8.327

4.  Impact of Platelet Volume on the Clinical Outcomes of Patients with Acute Coronary Syndrome.

Authors:  Hsien-Yuan Chang; Ling-Wei Hsu; Cheng-Han Lee; Chih-Chan Lin; Chen-Wei Huang; Po-Wei Chen; Po-Kai Yang; Yang-Che Hsueh; Ping-Yen Liu
Journal:  Acta Cardiol Sin       Date:  2019-11       Impact factor: 2.672

5.  Therapeutic effect of irbesartan combined with atorvastatin calcium in the treatment of rats with coronary heart disease.

Authors:  Tao Li; Weina Yao
Journal:  Exp Ther Med       Date:  2018-08-30       Impact factor: 2.447

Review 6.  The secretory phospholipase A2 group IIA: a missing link between inflammation, activated renin-angiotensin system, and atherogenesis?

Authors:  Dimitar Divchev; Bernhard Schieffer
Journal:  Vasc Health Risk Manag       Date:  2008

7.  Role of secretory phospholipase A₂ in women with metabolic syndrome.

Authors:  D Pop; A Sitar-Taut; G Bodisz; D Zdrenghea; M Cebanu; L Stanca
Journal:  Indian J Med Res       Date:  2013-12       Impact factor: 2.375

8.  Use of ivabradine and atorvastatin in emergent orthopedic lower limb surgery and computed tomography coronary plaque imaging and novel biomarkers of cardiovascular stress and lipid metabolism for the study and prevention of perioperative myocardial infarction: study protocol for a randomized controlled trial.

Authors:  Nima Rudd; Ivan Subiakto; Muhammad Asrar Ul Haq; Vivek Mutha; William J Van Gaal
Journal:  Trials       Date:  2014-09-07       Impact factor: 2.279

9.  Elevated Type II Secretory Phospholipase A2 Increases the Risk of Early Atherosclerosis in Patients with Newly Diagnosed Metabolic Syndrome.

Authors:  Chang-Qing Sun; Chun-Yan Zhong; Wei-Wei Sun; Hua Xiao; Ping Zhu; Yi-Zhang Lin; Chen-Liang Zhang; Hao Gao; Zhi-Yuan Song
Journal:  Sci Rep       Date:  2016-12-12       Impact factor: 4.379

10.  Mendelian Randomization Studies Promise to Shorten the Journey to FDA Approval.

Authors:  Robert Roberts
Journal:  JACC Basic Transl Sci       Date:  2018-11-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.